Structure Therapeutics Management
Management criteria checks 4/4
Structure Therapeutics' CEO is Raymond Stevens, appointed in May 2019, has a tenure of 6.58 years. total yearly compensation is $5.74M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 2.19% of the company’s shares, worth $103.44M. The average tenure of the management team and the board of directors is 3.8 years and 3 years respectively.
Key information
Raymond Stevens
Chief executive officer
US$5.7m
Total compensation
| CEO salary percentage | 11.05% |
| CEO tenure | 6.6yrs |
| CEO ownership | 2.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program
Dec 08Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Jun 24
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Mar 20We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Mar 11Structure Therapeutics: Competitive Data Is Emerging
Jan 03Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$211m |
| Jun 30 2025 | n/a | n/a | -US$179m |
| Mar 31 2025 | n/a | n/a | -US$143m |
| Dec 31 2024 | US$6m | US$634k | -US$123m |
| Sep 30 2024 | n/a | n/a | -US$111m |
| Jun 30 2024 | n/a | n/a | -US$100m |
| Mar 31 2024 | n/a | n/a | -US$98m |
| Dec 31 2023 | US$7m | US$596k | -US$90m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$66m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$747k | US$487k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$1m | US$420k | -US$44m |
Compensation vs Market: Raymond's total compensation ($USD5.74M) is about average for companies of similar size in the US market ($USD6.91M).
Compensation vs Earnings: Raymond's compensation has been consistent with company performance over the past year.
CEO
Raymond Stevens (61 yo)
Dr. Raymond C. Stevens, Ph.D. is Professor of Molecular Biology and Chemistry at The Scripps Research Institute, La Jolla, California since 1999 until July 2014. He has been the Chief Executive Officer at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$5.74m | 2.19% $ 103.4m | |
| Chief Scientific Officer & GM of Structure Shanghai | 6.4yrs | US$3.69m | 0.052% $ 2.4m | |
| Chief Medical Officer | 1.3yrs | US$3.45m | 0.012% $ 588.3k | |
| Co- Founder | 3.6yrs | US$3.67m | 2.54% $ 120.0m | |
| Chief Technology Officer | 3.3yrs | US$1.24m | 0.0073% $ 344.5k | |
| Senior Vice President of Legal | no data | no data | no data | |
| Senior Vice President of People | 2.1yrs | no data | no data | |
| Senior Vice President of Chemistry | 3.9yrs | no data | no data | |
| Executive VP & Head of Biology | no data | no data | no data | |
| Senior Vice President of Clinical Development Operations | no data | no data | no data | |
| Senior Vice President of Preclinical Development | no data | no data | no data | |
| Senior Vice President of Cardiopulmonary Clinical Development | 4.9yrs | no data | no data |
Experienced Management: GPCR's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$5.74m | 2.19% $ 103.4m | |
| Independent Director | 3.8yrs | US$472.17k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$850.90k | 0% $ 0 | |
| Independent Chairman | 3.9yrs | US$643.67k | 0.060% $ 2.8m | |
| Independent Director | 2.3yrs | US$429.04k | 0% $ 0 | |
| Independent Director | 3yrs | US$464.67k | 0% $ 0 | |
| Independent Director | 3yrs | US$464.67k | 0% $ 0 |
Experienced Board: GPCR's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 09:54 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Structure Therapeutics Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Samantha Lynn Semenkow | Citigroup Inc |